dnam 1  (Bioss)

Journal: Bioactive Materials

Article Title: Natural killer cell-inspired dendritic mesoporous rare-earth nanoparticles potentiate X-ray-triggered reactive oxygen generation for low-dose radiotherapy-radiodynamic therapy

doi: 10.1016/j.bioactmat.2026.02.011

Figure Lengend Snippet: In vitro targeted cell uptake and oxygen supply ability. (a) SDS-PAGE electrophoresis profiles and Western blot results of TSSI-Ce 6 C-DMTm, NKEV, and TSSI-Ce 6 C-DMTm@NKEV. (b) Scheme of the tumor-targeting mechanism of TSSI-Ce 6 C-DMTm@NKEV. (c) Western blot results of NK cells, NKEV, TSSI-Ce 6 C-DMTm@NKEV, and TSSI-Ce 6 C-DMTm to indicate the presence of DNAM-1 and NKG2D. (d) CLSM images and quantification analysis of MDA-MB-231 cells treated with TSSI-Ce 6 C-DMTm and TSSI-Ce 6 C-DMTm@NKEV for 1, 3, and 9 h. (f) Flow cytometry profiles and (g) CLSM images of MDA-MB-231 cells pretreated with different antibodies and treated with TSSI-Ce 6 C-DMTm@NKEV for 9 h. (h) CLSM images of MDA-MB-231 cells pretreated with H 2 O 2 and treated with different formulations via [Ru(dpp) 3 ]Cl 2 staining for hypoxia levels observation. ∗∗∗∗ p < 0.0001.

Article Snippet: Then, the membrane was blocked using 5% skim milk and incubated using primary antibody of anti -DNAM-1 (ABclonal, A23200), anti -NKG2D (Bioss, bs-0938R), anti -β-actin (Beijing Solarbio Science & Technology Co., Ltd.), anti-Na/K ATPase (Abcam, ab254025), respectively.

Techniques: In Vitro, SDS Page, Electrophoresis, Western Blot, Flow Cytometry, Staining

Journal: bioRxiv

Article Title: Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class I

doi: 10.64898/2026.03.03.708729

Figure Lengend Snippet: (A) Display of ULBP1 and CD155 on CombiCells detected by mAbs and NKG2D-Fc, and DNAM-1-Fc, respectively. (B&C) KIR2DL1+ and KIR2DL1-NK-cell degranulation (CD107a upregulation) in response to ULBP1, CD155, and HLA-C*05:01 displayed on CombiCells. (C) Three types of HLA-C*05:01 were tested, all containing P2 (IIDKSGSTV); wild-type, open and dipeptide exchanged. Data from three independent experiments with NK cells from separate donors are shown.

Article Snippet: For binding assays, APC-conjugated Fc fusion protein (NKG2D-Fc (R&D Systems, Cat. No: 1299-NK) or DNAM-1-Fc (R&D Systems, Cat. No: # 666-DN) or KIR-Fc (R&D Systems, KIR2DL1-Fc (Cat. No: 1844-KR-050), KIR2DL3-Fc (Cat. No: 2014-KR-050), KIR2DS4-Fc (Cat. No: 1847-KR-050) (3.6 μg mL -1 ) was added at 25 μL per well and incubated for 30 min at 4 °C in the dark.

Techniques: